Series 3 Ep7- Non-Invasive detection and diagnosis of breast cancer with Elizabeth Cormier-May

Radically improving the detection, diagnosis and treatment of women’s health-related disease.

Elizabeth Cormier-May and the team Mammogen are integrating data, science and the lived experiences from patients that they serve into the ongoing product development efforts related to their flagship breast cancer program.

Mammogen is a female-led biotechnology company focused on meaningfully improving the detection, diagnosis and treatment of women's health-related diseases, and creating an end-to-never-end community for women around the world.

 

Mammogen is centred around its proprietary genTRU™ liquid biopsy platform. The company's flagship genTRU breast™ program leverages novel messenger RNA (mRNA) technology to non-invasively detect and diagnose breast cancer.

Mammogen's core technology is a non-invasive screening solution intended for all women, but particularly for the under-40 population who aren't eligible for annual mammography and the 55+ population who are only recommended for mammography every other year.